Clinical Trial Update: Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating autologous peptide-induced active immunity as maintenance therapy for acute myeloid leukemia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Autologous peptide-induced active immunity (Autologous peptide-induced active immunity)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Acute Myeloid Leukemia, Personalized Active Immunotherapy | Phase 1 | Status: RECRUITING